NYSE:IBIO
Ibio Inc Stock News
$1.88
-0.0200 (-1.05%)
At Close: May 09, 2024
Disappointing iBio Is Too Far Behind to Make an Impact
12:24pm, Wednesday, 14'th Oct 2020
What was once a promising investment in IBIO stock has turned into an untenable case as setbacks mount higher.
iBio: Slow On COVID-19 Clinical Progress, A Viable Short Candidate (NYSEMKT:IBIO)
07:04pm, Wednesday, 07'th Oct 2020
A recent 10-Q for IBIO mentions the word plasma just once. IBIO isn't a plasma company like ADMA and isn't developing a plasma-derived product for COVID-19 like KMDA.
It's Hard to Trust iBio When It's Lagging the Competition
12:05pm, Wednesday, 23'rd Sep 2020
Not only that IBIO stock has suffered because the underlying company's prior candidates have failed to materialize.
Avoid iBio Stock In the Near-Term As Competitors Keep Racing Ahead
05:00pm, Wednesday, 16'th Sep 2020
At the moment, it’s better to just avoid iBio stock. There are far better opportunities to be found in this market.
9 Reasons Why The Race For Major COVID-19 Vaccine Revenues Has Greatly Narrowed
10:06am, Wednesday, 02'nd Sep 2020
The huge amount of Operation Warp Speed funding for its six vaccines has helped them become somewhat dominant leaders in the race for a sizable share of the market.
Vaccine Race Also-ran iBio Stock Won't See Earlier Highs Anytime Soon
09:01am, Friday, 28'th Aug 2020
Both the potential rewards and risks offered by IBIO stock are high. But for Covid-19 vaccine bets, there are better options for investors.
iBio: A Compelling Short
08:30am, Tuesday, 25'th Aug 2020
iBio has broken below a key technical level. The company is behind over 20 other names in COVID-19 vaccine development.
GlaxoSmithKline: Attention Is Now Shifting To Vaccine Manufacturing
09:39am, Friday, 21'st Aug 2020
Current state of COVID-19 vaccine production indicates that GSK is both in vaccine development and manufacturing.
Is iBio's (NYSEMKT:IBIO) 216% Share Price Increase Well Justified?
04:52pm, Wednesday, 19'th Aug 2020
iBio, Inc. (NYSEMKT:IBIO) shareholders might be rather concerned because the share price has dropped 60% in the last...
Xerox and Inozyme See Activist Action
08:55pm, Friday, 14'th Aug 2020
Icahn Capital lifted its position in printing and imaging firm Xerox to 25,269,522 shares. Longitude Capital initiated a position of 2,819,379 shares in Inozyme, a newly public biopharmaceutical firm.
It's Now Time for iBio to Deliver the Goods
11:55am, Tuesday, 11'th Aug 2020
If not, IBIO stock could end up stumbling on a narrowing window of opportunity.
iBio Is One of the Top Pandemic Opportunities
06:58pm, Monday, 10'th Aug 2020
With iBio's FastPharming technology and its vaccines in the works, IBIO stock is well worth gambling on at its current prices.
iBio Provides Update on IBIO-201 COVID-19 Vaccine Program
11:15am, Monday, 10'th Aug 2020
\- IBIO-201 Demonstrates Ability to Elicit anti-SARS-CoV-2 Immune Response in Preclinical Studies -NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Com
iBio Stock Is a Highly Speculative Covid-19 Play That Isn't Worth It
12:47pm, Wednesday, 05'th Aug 2020
Too much speculation and too-weak fundamentals make IBIO stock a sell today for risk-averse, disciplined investors.
There's a Better Way to Bet on iBio Stock if You Prefer Stability
12:03pm, Tuesday, 04'th Aug 2020
With the GERM ETF, you have a more well-rounded exposure to biotechnology and pharmaceuticals without the long shot proposition of IBIO stock.
